Member Info for Diplomat65

DonaldTrumpsWig

You’ve nailed it with your summary that an accurate, easy-to-use, anterior nasal LFD will put amend to this profligate abuse of public funds. The BBC item was reporting on an article in today’s online Guardian:

No evidence £22bn test-and-trace scheme cut Covid rates in England, say MPs
https://www.theguardian.com/world/2021/mar/10/no-evidence-22bn-test-and-trace-scheme-cut-covid-rates-in-england-say-mps?CMP=Share_iOSApp_Other

Doze:

Then won’t there be an equal opportunity for the Sovereign (“Affimer Inside”) test to show/disprove a PCR positive to be false regarding infectiousness of the individual?

Sir Al is quoted as saying (VOX interview) that Affimer-based lateral flow tests cannot be compared to PCR results.

I am enjoying listening out for subtle changes in the language being used now to counter negative press coverage of the inaccuracies of currently available rapid lateral flow devices.
Speaking on Times Radio this morning, Claire Wilson, Medical journalist with The New Scientist magazine was asked her opinion on the accuracy of the LFD’s being used in the Nation’s schools this week.
Acknowledging the high level of false negatives of around 50% associated with (unnamed but Innova’s) current test devices Claire Wilson was asked if these LFD’s can be improved upon?
Claire said “Yes, there are highly reliable tests coming forward but these first generation tests in use now are doing two important things; getting our children back into school and getting them familiar with the testing routines.”
First generation LFD’s. What a subtle slap in the face for Innova and what a smart way of building confidence in the next iteration— cue Avacta! GLA

Sir Al will insist on labelling indicating “Affimer Inside” à la Intel product protection My glass if half full Tall Paul.

Pasaca Capital (Innova) are in the game to make profit and they will not give up their lucrative market position easily. They are probably beating Avacta’s door down as we speak, begging for an Affimer®? supply agreement to protect their revenues and investment in their recently-announced UK manufacturing capability. Avacta are eager to sign up additional manufacturing partners too so all good as far as I’m concerned.

I agree, Innova were the only game in town in terms of availability so questionable performance became a secondary issue. However, complaints about inaccuracy and discomfort widely reported across all media will in my opinion helps as they pave the way for Avacta’s (Sovereign) test to be introduced as “the most accurate, easier to use and more comfortable Rapid test made right here in the UK by the best of British biotech companies.”
I imagine the positive press releases and launch promotions are being fine tuned as we wait. Patience required. GLA

I’m going with Tina Turner
https://youtu.be/wTm5-YZJ5q4

For what’s it’s worth, I read today’s move down as nothing more than the MM’s working the share price to shake out weak, undecided recent investors in order to collect stock to sell on when the Tsunami of news crashes onto the market. If you’re looking to the future, as I am, there is no reason to be concerned. My shareholding will be life-changing for me and my family so the MM’s can continue shaking the tree but me and my 156,216 shares are nailed on to this mighty oak. GLA LTH

Move along, there’s nothing to see here.
Biosure claim their “Know Now” saliva based rapid antigen test gives a result in 15 minutes. Their website, however, discloses a LoD (Level of Detection” of 500pg/ml compared to Avacta’s AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test which shows excellent analytical sensitivity of 50 pg/ml.
https://www.biosure.co.uk/tests/covid-19-antigen-test/

So much for that theory as we give up the earlier days gains lol

What about “Little Johnny” transmitting the virus Wyndrum?

Holidaymakers just need to invest in a stock of Avacta’s LFDs and test all family members before setting off for the airport.
Simples lol

Avacta describe their relationship with DHSC as a customer placing orders for tests - pretty straightforward. BUT “partner”? How does that work? Are DHSC investing into Avacta and taking a profit share? This makes no sense to me. Any wiser heads out there able to educate this duffer?

From this morning’s RNS:
“In the UK, the DHSC is a potential customer and partner in the roll out of such a validated test.”

“An Avacta test a day
Helps you work, rest or play”

Sound familiar? Lol

Clarifies the saliva speculation, confirms DHSC collaboration and overseas opportunities. Next stop market open then Boris Road Map presentation. Excitement continues to build. GLA
“ The press report this weekend incorrectly stated that a saliva-based rapid antigen test from Avacta had been evaluated at Porton Down. In fact, the evaluated test was the anterior nasal swab test that has subsequently generated the excellent initial clinical performance data outlined above. However, in its evaluation Porton Down used artificial samples and did not use clinical samples. ”

My old knees wouldn’t last 5 minutes in the Avacta Football team but happy to run the bar or sell programmes as a committed supporter. How about Huffington Post as shirt sponsor? GLA

Courtesy of Rivaldo posting on ADVFN board:
"CTA approval" moving to a clinical stage company

Confirmation that the MHRA has given CTA approval for Avacta to start its first clinical study with AVA6000 (pro-doxorubicin) is a major milestone - transforming the therapeutics business into a clinical stage company and further de-risking the pre|CISIONâ„¢ platform. Having filed the CTA on 23 December 2020, this will allow Avacta to start a Phase I study in a range of cancers to establish safety, tolerability and early efficacy signals. COVID-19 restrictions permitting, Avacta is targeting first patient dosing in mid-year, which should generate first data in H2 2021.

We make no changes to forecasts and reiterate our SOTP target price of 310p, c.60p of which relates to pre|CISION platform. A successful Phase I outcome would see a substantial uplift in our target valuation"

We need a strong positive press campaign to counter the steady flow of negative press and PR material aimed at the general public to undermine confidence in LFD’s.

I received an unsolicited email this afternoon from a company called Euro Environmental with Benefits and Challenges of Rapid Antigen Tests in the subject line.

Head Office,
Atlas 6, Balby Carr Bank,
Doncaster,
South Yorkshire,
DN4 5JT

https://www.euroenvironmental.co.uk/news/item/benefits-and-challenges-of-rapid-antigen-tests

As an Avacta shareholder it caught my attention so I opened it. I was disturbed by the damaging, negative spin their article puts on the limitations of LFD's while they were heavily promoting the use of PCR testing of saliva samples.

“Although the majority of rapid antigen tests use nasopharyngeal specimens, some commercially available test kits utilise swabs taken from the lower nasal region which makes testing less invasive and more tolerable for patients than nasopharyngeal swabs. Nasal specimens from the nostrils provide similar information to those from the back of the nose (nasopharyngeal ) and throat (oropharyngeal), as long as the specimen is of good quality. This can help avoid the operational drawbacks because an individual will be more likely to collect a good sample without discomfort.”

PCR testing, on the other hand, can use a simple saliva test which is much easier to collect, provides more consistent and reliable specimens, and has much higher sensitivity (accuracy).

Time for the big reveal?

Based on what I have read and heard Boris say at an earlier No 10 Press Briefing, the "Big Reveal" or the road map showing how we exit the current Lockdown will be shared either Monday 22nd of February or at some point during that week.

“Combined will generate several million tests per month” is a long way short of two million per day .. . . . Discuss